二磷酸腺苷受体抑制剂的评价与临床应用  

Evaluation and Clinical Application of Adenosine Diphosphate Receptor Antagonists

作　　者：张石革[1] 张国伟 

机构地区：[1]北京大学第四临床医学院北京积水潭医院,北京市100035 [2]甘肃省永登县中医院,兰州市730300

出　　处：《中国医院用药评价与分析》2007年第5期332-335,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:缘于血小板在血栓形成中占有重要地位,使影响血小板形态、积聚和活化功能的抗血小板药在不断地发展,本文旨在评价其临床进展和应用的侧面。方法:采用国内、外文献综述方法。结果与结论:二磷酸腺苷受体拮抗剂作为干预血小板生物学行为的一个途径,可降低高危患者发生心血管事件风险,防治经皮冠脉介入治疗者突发远端血管阻塞,显著降低心梗、脑卒中、肺或静脉血栓的发生率和死亡率。OBJECTIVE： The important role of the platelets played in the formation of thrombosis leads to the incessant development of those antiplatelet drugs that can affect the morphous, accumulation and mobilizing functions of platelets. This paper aimed to evaluate the clinical progress and application of antiplatelet drugs. METHODS： We reviewed the pertinent literature both at home and abroad. RESULTS ＆ CONCLUSION： Adenosine diphosphate receptor antagonists, which serve as a route to intervene the biological behavior of platelets, can reduce the risks of cardiovascular events in high risk patients, prevent and treat acute distal angiemphraxis in patients undergoing percutaneous coronary artery interventional therapy, significantly reduce the morbidity and mortality of myocardial infarction, stroke, and pulmonary embolism or phlebothrombosis.

关 键 词：血小板 二磷酸腺苷受体拮抗剂 心血管事件 合理应用 

分 类 号：R972[医药卫生—药品]